

# Shweta Urva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4158535/publications.pdf>

Version: 2024-02-01

9  
papers

1,451  
citations

1039406

9  
h-index

1473754

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

928  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 multipleâ€ascending dose study of tirzepatide in <scp>Japanese</scp> participants with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 239-246.	2.2	29
2	Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 418-429.	5.5	95
3	Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics, 2022, 61, 1057-1067.	1.6	16
4	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics, 2021, 60, 1049-1059.	1.6	27
5	The novel dual glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1 (<scp>GLP</scp>â€1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <scp>longâ€acting GLP</scp>â€1 receptor agonists. Diabetes, Obesity and Metabolism, 2020, 22, 1886-1891.	2.2	53
6	Efficacy and tolerability of tirzepatide, a dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist in patients with type 2 diabetes: A 12â€week, randomized, doubleâ€blind, placeboâ€controlled study to evaluate different doseâ€escalation regimens. Diabetes, Obesity and Metabolism, 2020, 22, 938-946.	2.2	126
7	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020, 5, .	2.3	177
8	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet, The, 2018, 392, 2180-2193.	6.3	528
9	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 2018, 18, 3-14.	3.0	400